Lawrence Albers to Humans
This is a "connection" page, showing publications Lawrence Albers has written about Humans.
Connection Strength
0.075
-
Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008 Jan; 17(1):61-75.
Score: 0.015
-
Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol. 2005 Apr; 25(2):170-4.
Score: 0.013
-
Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004 Feb; 11(3):297-312.
Score: 0.012
-
Ramaswamy S, Driscoll D, Reist C, Smith LM, Albers LJ, Rose J, Nguyen L, Monga V, Doria R, Hollifield M. A Double-Blind, Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder and Comorbid Depression. Prim Care Companion CNS Disord. 2017 Aug 24; 19(4).
Score: 0.008
-
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11; 318(2):132-145.
Score: 0.007
-
Mercolini L, Mandrioli R, Protti M, Conca A, Albers LJ, Raggi MA. Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients. Bioanalysis. 2014 Jun; 6(11):1487-95.
Score: 0.006
-
Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, Wid?n J, Svensson JO, Albers LJ, Kennedy JL, Endrenyi L, Kalow W. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics. 2007 May; 17(5):339-47.
Score: 0.004
-
Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007 Feb; 27(1):46-51.
Score: 0.004
-
Saracino MA, Mercolini L, Flotta G, Albers LJ, Merli R, Raggi MA. Simultaneous determination of fluvoxamine isomers and quetiapine in human plasma by means of high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 07; 843(2):227-33.
Score: 0.003
-
Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE, Caligiuri M, Lohr JB, Reist C. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006 Feb; 7(2):119-33.
Score: 0.003